US · EBS · BIOTECHNOLOGY
Emergent BioSolutions Inc. (EBS) intrinsic value and stock valuation
$5.05as of 2026-11-21 · Mkt cap 389.04M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Emergent BioSolutions Inc. DCF and intrinsic value
InvestorsCraft values EBS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from EBS’s statements →
Emergent BioSolutions Inc. Graham Number
Graham Number: $14.70d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $742.9M | $1.04B | $1.05B | $1.12B | $1.77B |
| Operating income | $110.2M | -$-108.7M | -$-726.4M | -$-170M | $341.4M |
| Net income | $52.6M | -$-190.6M | -$-760.5M | -$-211.6M | $219.5M |
| EPSd | $927.7K | -$-3.6M | -$-14.85M | -$-4.22M | $4.06M |
| Operating cash flow | $170.6M | $58.7M | -$-206.3M | -$-34.1M | $321.1M |
| Capital expenditure | -$-13.8M | -$-22.9M | -$-51.6M | -$-115.8M | -$-225M |
| Free cash flow | $156.8M | $35.8M | -$-257.9M | -$-149.9M | $96.1M |
| Total assets | $1.32B | $1.39B | $1.82B | $3.17B | $2.96B |
| Total debt | $572.1M | $676.1M | $860.2M | $1.43B | $871M |
| Net debt | $366.7M | $576.6M | $748.5M | $783.8M | $294.7M |
| Total equity | $522.6M | $482.8M | $649.3M | $1.39B | $1.61B |
| Cash and short-term investments | $205.4M | $99.5M | $111.7M | $642.6M | $576.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $742.9M | $1.04B | $1.05B | $1.12B | $1.77B |
| Cost of revenue | $392.3M | $668.2M | $689.3M | $644.5M | $980.4M |
| Gross profit | $350.6M | $375.4M | $360M | $473M | $793.2M |
| Research and development expenses | $53.8M | $70.7M | $111.4M | $188.3M | $235.2M |
| Selling, general and administrative expenses | $186.6M | $298.7M | $356.7M | $339.5M | $348.7M |
| Other expenses | $0.00 | $114.7M | $618.3M | $115.2M | -$-132.1M |
| Operating expenses | $240.4M | $484.1M | $1.09B | $643M | $451.8M |
| Cost and expenses | $632.7M | $1.15B | $1.78B | $1.29B | $1.43B |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $59.3M | $71M | $87.9M | $37.3M | $34.5M |
| Depreciation and amortization | $98.3M | $105.6M | $121.1M | $125M | $118.2M |
| Ebitda | $240.4M | $53.4M | -$-47M | $15.7M | $504.2M |
| Operating income | $110.2M | -$-108.7M | -$-726.4M | -$-170M | $341.4M |
| Total other income/expenses, net | -$-27.4M | -$-34.2M | -$-4.8M | -$-49M | -$-38.2M |
| Income before tax | $82.8M | -$-142.9M | -$-731.2M | -$-219M | $303.2M |
| Income tax expense | $30.2M | $47.7M | $29.3M | -$-7.4M | $83.7M |
| Net income | $52.6M | -$-190.6M | -$-760.5M | -$-211.6M | $219.5M |
| Weighted average shares outstanding | $53.5M | $53M | $51.2M | $50.1M | $53.5M |
| Weighted average diluted shares outstanding | $56.7M | $53M | $51.2M | $50.1M | $54.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $205.4M | $99.5M | $111.7M | $642.6M | $576.3M |
| Net receivables | $84.2M | $154.5M | $191M | $159.2M | $278.9M |
| Inventory | $343.4M | $311.7M | $328.9M | $350.7M | $344.5M |
| Total current assets | $662.5M | $598.7M | $679.5M | $1.21B | $1.27B |
| Property, plant and equipment, net | $205.4M | $270.6M | $399M | $837M | $828.4M |
| Goodwill and intangible assets | $436.5M | $501.5M | $566.6M | $947M | $829.5M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $656.1M | $791M | $1.14B | $1.96B | $1.69B |
| Total assets | $1.32B | $1.39B | $1.82B | $3.17B | $2.96B |
| Accounts payable | $55.6M | $60.9M | $112.2M | $103.5M | $128.9M |
| Short-term debt | $0.00 | $2.7M | $413.7M | $963.1M | $37.4M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $26.4M | $11.7M |
| Total current liabilities | $132.2M | $162.4M | $651.3M | $1.23B | $374M |
| Long-term debt | $572.1M | $673.4M | $446.5M | $463.3M | $833.6M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $4.7M |
| Total non-current liabilities | $663.8M | $744.5M | $522.6M | $549.7M | $972.2M |
| Capital lease obligations | $0.00 | $9.7M | $0.00 | $14.8M | $24.2M |
| Total liabilities | $796M | $906.9M | $1.17B | $1.78B | $1.35B |
| Common stock | $100K | $100K | $100K | $100K | $100K |
| Retained earnings | -$-159.8M | -$-212.4M | -$-21.8M | $738.7M | $950.3M |
| Accumulated other comprehensive income (loss) | -$-7.5M | -$-5.2M | -$-5.7M | $3.1M | -$-16.1M |
| Total equity | $522.6M | $482.8M | $649.3M | $1.39B | $1.61B |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $572.1M | $676.1M | $860.2M | $1.43B | $871M |
| Net debt | $366.7M | $576.6M | $748.5M | $783.8M | $294.7M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $52.6M | -$-190.6M | -$-760.5M | -$-211.6M | $230.9M |
| Depreciation and amortization | $95.8M | $108.8M | $125.1M | $143.3M | $123.8M |
| Stock-based compensation | $16.2M | $18M | $23.1M | $45.1M | $42.4M |
| Change in working capital | -$-22.4M | $88.7M | -$-70.3M | -$-2.1M | -$-156.4M |
| Accounts receivable | $25.5M | -$-24.4M | -$-21.6M | $118.1M | -$-48.2M |
| Inventory | -$-30.3M | -$-24.5M | $600K | -$-57.1M | -$-44M |
| Accounts payable | -$-8.4M | -$-33M | $10.6M | -$-14M | -$-2.5M |
| Net cash provided by operating activities | $170.6M | $58.7M | -$-206.3M | -$-34.1M | $321.1M |
| Investments in property, plant and equipment | -$-13.8M | -$-22.9M | -$-51.6M | -$-115.8M | -$-225M |
| Acquisitions, net | $0.00 | $0.00 | $270.2M | $0.00 | $0.00 |
| Net cash used for investing activities | $69.4M | $125.2M | $212.3M | -$-381.3M | -$-225M |
| Common stock issued | $2.2M | $9.3M | $8.4M | $0.00 | $0.00 |
| Common stock repurchased | -$-24.9M | $0.00 | $0.00 | -$-82.1M | -$-106M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-136.6M | -$-190M | -$-535.7M | $481.2M | -$-141M |
| Net change in cash | $103.5M | -$-6.1M | -$-530.9M | $66.3M | -$-45.2M |
| Cash at end of period | $209.1M | $105.6M | $111.7M | $642.6M | $576.3M |
| Operating cash flow | $170.6M | $58.7M | -$-206.3M | -$-34.1M | $321.1M |
| Capital expenditure | -$-13.8M | -$-22.9M | -$-51.6M | -$-115.8M | -$-225M |
| Free cash flow | $156.8M | $35.8M | -$-257.9M | -$-149.9M | $96.1M |
Line items
Line items
Line items
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
- CEO
- Joseph C. Papa Jr.
- Employees
- 900
- Beta
- 2.34
Included in
Explore
Frequently asked questions
What is the intrinsic value of Emergent BioSolutions Inc. (EBS)?
InvestorsCraft does not currently publish an intrinsic value for EBS. How the IC value is calculated.
Is EBS undervalued?
InvestorsCraft does not publish an undervaluation signal for EBS at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.